2023
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics
Lokeshwar S, Choksi A, Haltstuch D, Rahman S, Press B, Syed J, Hurwitz M, Kim I, Leapman M. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics. World Journal Of Urology 2023, 41: 2007-2019. PMID: 37160450, DOI: 10.1007/s00345-023-04409-9.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyHormone-sensitive prostate cancerSensitive prostate cancerPositron emission tomographyConventional computerized tomographyDocetaxel chemotherapyClinical trialsProstate cancerCombination of ADTBackbone of treatmentCytoreductive radical prostatectomySequencing of therapyFirst-line treatmentEvaluation of patientsClinical practice guidelinesOngoing clinical trialsAndrogen receptor antagonistPubMed Medline databaseDeprivation therapyInitial managementOverall survivalStaging evaluationBone scanRandomized trials
2019
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Mohler J, Antonarakis E, Armstrong A, D'Amico A, Davis B, Dorff T, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Ippolito J, Kane C, Kuettel M, Lang J, McKenney J, Netto G, Penson D, Plimack E, Pow-Sang J, Pugh T, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small E, Spratt D, Srinivas S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 479-505. PMID: 31085757, DOI: 10.6004/jnccn.2019.0023.Peer-Reviewed Original ResearchConceptsProstate cancerRisk stratificationNCCN Clinical Practice GuidelinesMultigene molecular testingSecondary hormonal therapyAndrogen deprivation therapySomatic genetic testingClinical practice guidelinesDeprivation therapyHormone therapyLocalized diseaseAdvanced diseaseNCCN GuidelinesTreated patientsTreatment optionsMolecular testingProstateGenetic testingCancerTherapyPractice guidelinesPatientsNCCNDiseaseGuidelines
2016
The impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
Hafez N, Wang R, Hurwitz M, Ma X, Petrylak D. The impact of androgen deprivation and pelvic radiation on the development of bladder cancer. Journal Of Clinical Oncology 2016, 34: 439-439. DOI: 10.1200/jco.2016.34.2_suppl.439.Peer-Reviewed Original ResearchAndrogen deprivation therapyUrothelial bladder cancerProstate cancer patientsSecondary bladder cancerBladder cancerCancer patientsRadiation therapyAndrogen deprivationProstate cancerRecurrent urothelial bladder cancerElderly prostate cancer patientsCox proportional modelingRetrospective cohort studyKaplan-Meier analysisSEER-Medicare databaseSimilar patient populationsProstate cancer treatmentPrimary prostate cancerDeprivation therapyMedian followPelvic radiationCohort studyMale predilectionProportional modelingPatient populationProstate Cancer, Version 1.2016.
Mohler J, Armstrong A, Bahnson R, D'Amico A, Davis B, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Kane C, Kawachi M, Kuettel M, Lee R, Meeks J, Penson D, Plimack E, Pow-Sang J, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus T, Small E, Sonpavde G, Srinivas S, Strope S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 1.2016. Journal Of The National Comprehensive Cancer Network 2016, 14: 19-30. PMID: 26733552, DOI: 10.6004/jnccn.2016.0004.Peer-Reviewed Original ResearchConceptsProstate cancerMetastatic castration-recurrent prostate cancerCastration-recurrent prostate cancerTreatment of recurrent diseaseDiagnosis of prostate cancerRisk stratification methodsTreatment of menMetastatic diseaseRecurrent diseaseSystemic therapyNCCN GuidelinesHigh riskDiseaseDisease monitoringCancerNCCNManagement optionsStratification methodTreatmentRiskOptionsProstateTherapyGuidelinesDiagnosis